Cue Biopharma Inc EV/EBITDA
What is the EV/EBITDA of Cue Biopharma Inc?
The EV/EBITDA of Cue Biopharma Inc is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on NASDAQ compared to Cue Biopharma Inc
What does Cue Biopharma Inc do?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Companies with ev/ebitda similar to Cue Biopharma Inc
- Trilogy International Partners has EV/EBITDA of N/A
- Worldwide has EV/EBITDA of N/A
- Myanmar Investments International has EV/EBITDA of N/A
- Oshidori International has EV/EBITDA of N/A
- Target Capital has EV/EBITDA of N/A
- Gold State Resources has EV/EBITDA of N/A
- Cue Biopharma Inc has EV/EBITDA of N/A
- Entheon Biomedical has EV/EBITDA of N/A
- Vantex Resources Ltd has EV/EBITDA of N/A
- Made.Com Plc Ord Gbp0.000 has EV/EBITDA of N/A
- Skychain Technologies has EV/EBITDA of N/A
- 5paisa Capital has EV/EBITDA of N/A
- Catenae Innovation Plc has EV/EBITDA of N/A